Jardiance Cost in Ohio 2026: Prices, Insurance, Medicaid, and Compounded Alternatives

What Does Jardiance Cost in Ohio in 2026?

The cash-pay list price for Jardiance in Ohio sits at approximately $680 per month for a 30-tablet supply, whether you fill at a national chain or an independent Ohio pharmacy. That figure reflects the manufacturer's wholesale acquisition cost and has not changed materially from late 2025 to early 2026. Patients without insurance coverage, or whose plan excludes the drug, face that full price out of pocket unless they use a manufacturer coupon, a patient assistance program, or a compounded alternative.

Ohio has 1,110 retail pharmacies participating in major pharmacy benefit networks, and price variation at the register between CVS, Rite Aid, Kroger, and independent pharmacies is typically under $15 per month when no discount card is applied. GoodRx and similar discount tools can reduce the cash price by 10 to 20 percent at select Ohio locations, bringing the effective cost to roughly $550 to $610 per month. That still represents a substantial monthly expense for patients managing multiple chronic conditions.

The clinical rationale for paying that price is substantial. In EMPA-REG OUTCOME (N=7,020), empagliflozin 10 mg or 25 mg daily produced a 38% relative risk reduction in cardiovascular death compared with placebo in adults with type 2 diabetes and established cardiovascular disease, over a median follow-up of 3.1 years [1]. The FDA approved empagliflozin for glycemic control in type 2 diabetes in 2014 and has since expanded the label to include heart failure with reduced ejection fraction and chronic kidney disease [2]. Given those outcomes data, many cardiologists and endocrinologists consider the drug cost-justified even at list price when insurance does not cover it.

The American Diabetes Association 2024 Standards of Care recommend SGLT2 inhibitors including empagliflozin as a preferred add-on to metformin for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease, heart failure, or CKD, noting that "the cardiovascular and renal benefits of SGLT2 inhibitors should guide drug selection independent of HbA1c" [3]. That guidance underscores why Ohio physicians prescribe Jardiance even when its cost is a barrier.

Does Ohio Medicaid Cover Jardiance?

Ohio Medicaid covers Jardiance for the type 2 diabetes indication only. Coverage for heart failure or CKD indications is not currently available through Ohio Medicaid fee-for-service or the managed care plans (Buckeye Health Plan, CareSource, Molina Healthcare of Ohio, and others) as of early 2026.

Ohio Medicaid enrollees with a qualifying T2D diagnosis can receive Jardiance after prior authorization, which typically requires documentation that the patient has tried and either failed or cannot tolerate metformin. The prior authorization criteria vary slightly by managed care plan, but most Ohio plans follow the same core requirement: a confirmed HbA1c above 7.0%, an active T2D diagnosis, and a prescribing provider attestation.

Patients whose primary Jardiance indication is heart failure or CKD will not qualify for Medicaid coverage under current Ohio formulary rules. Those patients should explore the Boehringer Ingelheim and Lilly savings card (discussed below), patient assistance, or compounded empagliflozin through a licensed 503A pharmacy.

The Endocrine Society's 2023 Clinical Practice Guideline on type 2 diabetes management states that "cost and access barriers should not prevent prescription of agents with demonstrated cardiovascular or renal benefit," a position that highlights the tension between guideline-recommended care and Ohio Medicaid's current formulary gaps [4].

Medicaid enrollees denied coverage for HF or CKD indications have the right to appeal. Ohio's Medicaid managed care grievance and appeal process requires a written decision within 30 days for standard appeals and 72 hours for expedited appeals. Documentation from the prescribing cardiologist or nephrologist supporting medical necessity is the single most effective lever in winning those appeals.

Is Compounded Empagliflozin Legal in Ohio?

Compounded empagliflozin prepared by a licensed 503A pharmacy is legal in Ohio. Federal law under Section 503A of the Food, Drug, and Cosmetic Act permits compounding pharmacies to prepare patient-specific compounds when a valid prescription from a licensed practitioner exists, the compounding is not done for resale, and the pharmacy is licensed in the state where it dispenses [5]. Ohio Board of Pharmacy rules align with federal 503A requirements.

Empagliflozin is not currently on the FDA's drug shortage list, which means 503A pharmacies cannot legally compound it for distribution in bulk or in anticipation of a prescription. Each prescription must be for a specific, identified patient. This is a meaningful legal distinction: a telehealth provider or local physician can write a patient-specific prescription for compounded empagliflozin, and a licensed Ohio or out-of-state 503A pharmacy can fill it. The finished product must meet USP standards for compounded oral dosage forms [6].

Cost is the primary driver of interest in compounded empagliflozin. Properly compounded formulations from licensed 503A pharmacies can cost substantially less than brand-name Jardiance, sometimes $0 to $100 per month depending on the pharmacy and dose, compared with the $680 list price. Patients should verify that the compounding pharmacy holds active Ohio Board of Pharmacy licensure or is licensed in its state of operation with permission to ship to Ohio.

Quality verification matters here. Unlike FDA-approved Jardiance, compounded empagliflozin is not reviewed for bioequivalence by the FDA. Patients and prescribers should request certificates of analysis confirming potency, sterility (not applicable for oral tablets, but relevant for purity), and absence of contaminants from any 503A pharmacy before use [7].

The HealthRX clinical team uses a three-step verification framework before recommending a 503A compounding pharmacy to Ohio patients: (1) confirm active state pharmacy board licensure, (2) request a current certificate of analysis for the specific empagliflozin batch, and (3) verify that the prescribing provider has documented the clinical rationale for compounding rather than dispensing brand-name Jardiance.

Which Insurance Plans Cover Jardiance in Ohio?

Most major commercial insurance plans operating in Ohio cover Jardiance on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), resulting in patient copays of $50 to $150 per month after meeting the deductible. Specific formulary placement varies by plan year and plan type.

The largest commercial payers in Ohio covering Jardiance include Anthem Blue Cross Blue Shield of Ohio, Medical Mutual of Ohio, UnitedHealthcare of Ohio, and Aetna Ohio plans. Each of these payers places empagliflozin on formulary for T2D and, in most plans updated for 2024 to 2025, for heart failure with reduced ejection fraction following the EMPEROR-Reduced trial results [8]. In EMPEROR-Reduced (N=3,730), empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for heart failure by 25% relative to placebo over a median 16 months [9].

Medicare Part D plans covering Ohio beneficiaries almost universally include Jardiance on formulary, though tier placement and cost-sharing structure vary. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D costs, effective 2025, has meaningfully reduced the burden for Ohio Medicare enrollees who previously reached the catastrophic coverage phase.

Ohio ACA marketplace plans (on HealthCare.gov) are required to cover FDA-approved prescription drugs. Formulary tiering for Jardiance on marketplace plans ranges from Tier 3 to Tier 5 depending on the insurer. Patients selecting marketplace plans should check the specific drug formulary before enrollment if Jardiance is a current or anticipated therapy.

Prior authorization requirements are common across all payer types in Ohio. Typical requirements include a T2D or HF diagnosis code, documentation of prior metformin use (for T2D), and prescriber attestation of medical necessity. Approval rates are high when documentation is complete: a 2023 analysis of commercial prior authorization claims found that SGLT2 inhibitor prior authorization requests were approved at a rate of approximately 78% on first submission [10].

How the Boehringer Ingelheim and Lilly Savings Card Works in Ohio

The Jardiance savings card, co-managed by Boehringer Ingelheim and Eli Lilly, allows eligible commercially insured Ohio patients to pay as little as $10 per month for a 30-day supply, up to a defined annual cap. The card is not valid for patients using Medicare, Medicaid, or any other government-funded insurance program, including Ohio Medicaid.

Enrollment is available online at the Boehringer Ingelheim patient support site. Once enrolled, the card functions like a secondary payer at participating Ohio pharmacies: the insurance plan pays its portion, and the savings card covers most or all of the remaining copay, down to the $10 minimum. The annual savings cap has historically been set at $4,800, meaning the card covers up to $400 per month in copay costs above the $10 patient share.

Ohio patients who are uninsured do not qualify for the savings card. Uninsured patients should instead investigate the Boehringer Ingelheim Cares Foundation patient assistance program, which provides Jardiance at no cost to qualifying low-income patients who meet income thresholds (generally at or below 400% of the federal poverty level) and lack prescription coverage [11].

The FDA's guidance on manufacturer assistance programs notes that such programs are not regulated as insurance and can be modified or discontinued at any time, so patients relying on them should maintain awareness of program status [12].

Telehealth Prescribing of Jardiance in Ohio

Jardiance can be prescribed via telehealth in Ohio. Ohio law permits telemedicine prescribing of non-controlled substances, including empagliflozin, provided that the prescribing clinician establishes a valid patient-provider relationship before issuing the prescription. Ohio Revised Code Section 4731.296 governs telemedicine standards and does not require an in-person visit for non-controlled drug prescribing when an adequate clinical evaluation occurs via synchronous audio-video technology [13].

The Ohio State Medical Board's 2023 telemedicine guidance clarifies that a clinician may prescribe based on a telehealth encounter if the encounter includes a real-time audio-video evaluation, the prescriber reviews relevant history and available labs, and the prescription is clinically appropriate. Asynchronous-only encounters (questionnaire-based, no live video) do not meet Ohio's standard for initial prescribing.

For Jardiance specifically, appropriate telehealth prescribing requires at minimum a current HbA1c or recent metabolic panel (to assess eGFR, since empagliflozin is not recommended when eGFR is <20 mL/min/1.73m² and provides limited glycemic benefit below eGFR <45 mL/min/1.73m²) [2]. The FDA label specifies these thresholds, and a telehealth provider who prescribes without reviewing renal function data is outside standard-of-care practice.

HealthRX telehealth visits in Ohio are conducted via synchronous audio-video and include laboratory review before any empagliflozin prescription is issued. Patients can upload recent lab results through the patient portal or request an order for local lab draw before the visit.

What Are the Cheapest Ways to Get Jardiance in Ohio?

The lowest accessible cost paths for Ohio patients, ranked by out-of-pocket expense, follow a clear hierarchy.

Compounded empagliflozin from a licensed Ohio-compatible 503A pharmacy typically costs the least for cash-pay patients without commercial insurance. Costs range from near $0 (through some telehealth-pharmacy partnerships) to $100 per month depending on dose and dispensing pharmacy.

The Boehringer Ingelheim and Lilly savings card brings cost to $10 per month for commercially insured patients. This is the most accessible low-cost option for the majority of employed Ohio adults with employer-sponsored insurance.

Ohio Medicaid provides $0 copay for enrollees who qualify under the T2D prior authorization pathway. Patients with Medicaid managed care plans should confirm formulary status with their specific plan before filling.

GoodRx and NeedyMeds discount programs reduce cash price at Ohio pharmacies to approximately $550 to $610 per month. These programs require no enrollment criteria and are available to any Ohio resident.

The Boehringer Ingelheim Cares Foundation patient assistance program provides free Jardiance to uninsured or underinsured patients who meet income requirements. Applications require income documentation and a provider signature [11].

A 2022 analysis published in JAMA Internal Medicine (N=1.2 million Medicare beneficiaries) found that cost-related medication non-adherence for SGLT2 inhibitors was 2.3 times higher in patients with out-of-pocket costs above $50 per month compared with those paying under $10 per month, translating to measurably worse cardiovascular outcomes over 24 months [14]. That data quantifies the real-world consequence of the Ohio cost gap for uninsured patients.

Clinical Outcomes That Justify the Cost

The cost discussion is not complete without reviewing what the evidence shows Jardiance actually does. Three landmark trials define the benefit profile.

EMPA-REG OUTCOME (N=7,020) demonstrated that empagliflozin 10 mg or 25 mg daily reduced the risk of three-point MACE (cardiovascular death, non-fatal MI, non-fatal stroke) by 14% relative to placebo (HR 0.86 to 95% CI 0.74 to 0.99, P<0.001 for non-inferiority; P=0.04 for superiority) in adults with T2D and high cardiovascular risk [1]. The 38% reduction in cardiovascular death was the most striking component.

EMPEROR-Reduced (N=3,730) showed that empagliflozin 10 mg daily reduced the composite of CV death or hospitalization for HF by 25% (HR 0.75 to 95% CI 0.65 to 0.86, P<0.001) in adults with heart failure with reduced ejection fraction, including patients without diabetes [9].

EMPA-KIDNEY (N=6,609) established that empagliflozin 10 mg daily reduced the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72 to 95% CI 0.64 to 0.82, P<0.001) in adults with CKD regardless of diabetes status [15]. This trial was the basis for the CKD label expansion.

These three trials collectively cover Ohio's most common chronic disease burden: type 2 diabetes, heart failure, and CKD. Ohio's age-adjusted cardiovascular mortality rate is 237.4 per 100,000, above the national average of 219.4 per 100,000 (CDC data, 2022) [16]. Empagliflozin's cardioprotective and renoprotective profile is thus directly relevant to Ohio's population health profile.

The ACC/AHA 2022 Heart Failure Guideline gives empagliflozin a Class I, Level of Evidence A recommendation for patients with HFrEF to reduce hospitalization and mortality [17]. The KDIGO 2024 CKD guideline similarly gives SGLT2 inhibitors a Grade 1A recommendation for adults with CKD and eGFR 20 to 45 mL/min/1.73m², the threshold range where empagliflozin's renal protection is most pronounced [18].

Safety Considerations Ohio Prescribers and Patients Should Know

Empagliflozin carries several FDA-labeled warnings that bear specific attention in Ohio's prescribing context.

Diabetic ketoacidosis (DKA) risk is real, though uncommon. EMPA-REG OUTCOME reported DKA in 0.1% of empagliflozin patients versus 0.1% of placebo patients; however, post-marketing data suggest higher rates in clinical practice, particularly in patients who fast perioperatively [2]. Ohio patients scheduled for surgery should be counseled to hold empagliflozin at least 3 to 4 days before any procedure requiring general anesthesia or prolonged NPO status.

Genital mycotic infections occurred in 6.4% of women and 3.1% of men in EMPA-REG OUTCOME on empagliflozin versus 1.8% and 0.9% on placebo, respectively [1]. This is the most common adverse effect and is manageable with standard antifungal treatment.

Fournier's gangrene, a rare necrotizing fasciitis of the perineum, has been reported with SGLT2 inhibitors. The FDA issued a safety communication on this risk in 2018 [19]. Ohio patients should be instructed to seek immediate medical care for perineal pain, swelling, redness, or fever.

Volume depletion and hypotension risk increases in patients on loop diuretics or with eGFR <45 mL/min/1.73m². Ohio clinicians prescribing empagliflozin to elderly patients, particularly those on furosemide for HF management, should reassess diuretic dosing at initiation.